Invivyd, Inc. (IVVD)
(Delayed Data from NSDQ)
$1.11 USD
-0.03 (-2.63%)
Updated Sep 17, 2024 03:59 PM ET
After-Market: $1.11 0.00 (0.00%) 5:38 PM ET
3-Hold of 5 3
C Value C Growth C Momentum B VGM
Price, Consensus and EPS Surprise
IVVD 1.11 -0.03(-2.63%)
Will IVVD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IVVD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IVVD
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
All You Need to Know About Invivyd, Inc. (IVVD) Rating Upgrade to Strong Buy
IVVD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Invivyd (IVVD) Surges on Positive Data From COVID-19 Study
Invivyd (IVVD) Stock Rises 18% in 3 Months: Here's Why
Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?
Other News for IVVD
Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA? (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19
Invivyd announces business readiness update, granted EUA for PEMGARDA
Invivyd to Participate in Upcoming Investor Conferences
Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA?
Invivyd doses first participants in Phase 1 trial of VYD2311